ALGS

Aligos Therapeutics, Inc.
CAPPED RATING

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Aligos Therapeutics, Inc. (ALGS) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D+). The rating has held at C for 4 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.4 / 5.0
C
Value
B
Factor Score 3.4 / 5.0
Growth
C
Factor Score 2.4 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
D+
Factor Score 1.6 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -0.3
EV / EBITDA 0.1
Rev Growth YoY 287.2%
Gross Margin N/M
Price Return 3M -75.4%
Price Return 12M -72.7%
Catalyst Signal 0.00
Market Cap $10.4M
TTM Revenue $33.6M
Price / Sales 0.3
ROE -159.5%

Historical Factor Score Progression

Held C for 4 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B (3.4) C (2.4) D+ (1.8) D+ (1.6) C+ (2.6) C (2.4)
2026-11-10 B (3.4) D (1.4) C- (1.9) D+ (1.8) C+ (2.6) C (2.2)
2026-11-03 B- (3.0) D (1.3) C- (1.9) C+ (2.6) C+ (2.7) C (2.3)
2026-10-27 B- (3.0) D (1.3) C- (1.9) C+ (2.5) C+ (2.6) C (2.3)
2026-10-20 B- (3.0) D (1.3) C- (1.9) C- (2.1) C+ (2.6) C (2.2)
Page 1 of 8
…